( March 26, 2026, 8:19 AM EDT) -- WASHINGTON, D.C. — The maker of a gene therapy product is seeking en banc rehearing of a Federal Circuit U.S. Court of Appeals finding that a Delaware federal judge wrongly concluded that a patent’s claims involving genetically engineered cultured host cells containing a recombinant nucleic acid molecule were directed to a natural phenomenon; the petitioner tells the Federal Circuit that its opinion creates a sweeping rule regarding the patentability of creation that stems from natural DNA....